Brief: Tempest Receives Clearance To Proceed With Pivotal Trial Of Amezalpat Combination Therapy For First-Line Hcc In China
30/06/2025 13:22
Tempest Therapeutics Inc TPST.O: TEMPEST RECEIVES CLEARANCE TO PROCEED WITH PIVOTAL TRIAL OF AMEZALPAT COMBINATION THERAPY FOR FIRST-LINE HCC IN CHINA Source text: ID:nGNX32B2M1 Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T